GILD Archives - Page 27 of 29

1 minute read

Caribou’s Blood Cancer Candidate Shows Response Rates Better Than Novartis,’ This Analyst Writes

August 18, 2:14 PM

Last week, Caribou Biosciences Inc (NASDAQ:CRBU) announced Q2 earnings and provided updated results from the Phase 1 ANTLER trial of the company’s…

CRBU

1 minute read

After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy

By Vandana Singh

August 16, 7:43 AM

Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…

GILD

2 minute read

M&A
News

Gilead Announced Monday it Would Acquire Remaining Worldwide Rights of Trodelvy from Everest Medicines for $280M Upfront Plus Up to $175M in Milestones

By Charles Gross

August 16, 5:23 AM

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

GILD

4 minute read

Recap Of Monday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 15, 6:58 PM

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…

ANIX

2 minute read

Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday

By Lisa Levin

August 15, 1:02 PM

Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month.

AMTD

1 minute read

Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study

By Ragothaman Srinivasan

August 15, 10:17 AM

Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

GILD

2 minute read

Gilead Sciences Announces Trodelvy Significantly Improves Overall Survival In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In The TROPiCS-02 Study

By Benzinga Newsdesk

August 15, 8:42 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3

GILD

1 minute read

Moody’s Affirms Gilead At A3; Revises Outlook To Stable From Negative

By Bill Haddad

August 4, 2:04 PM

-Reuters

GILD

1 minute read

Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm

By Vandana Singh

August 4, 12:13 PM

Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists…

GILD

2 minute read

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

By Robert Kuczmarski

August 3, 2:23 PM

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

ABBV

Feed Symbols: GILD